lifileucel TIL Amtagvi
Selected indexed studies
- Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. (J Immunother Cancer, 2022) [PMID:36600653]
- Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. (J Clin Oncol, 2021) [PMID:33979178]
- Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. (J Immunother Cancer, 2024) [PMID:38423748]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. (2022) pubmed
- Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. (2021) pubmed
- Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. (2024) pubmed
- Lifileucel: First Approval. (2024) pubmed
- Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi). (2024) pubmed
- A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies. (2025) pubmed
- Current perspectives on Lifileucel tumor-infiltrating lymphocyte therapy: A paradigm shift in immunotherapy. (2025) pubmed
- Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps. (2025) pubmed
- Lifileucel: FDA-approved T-cell therapy for melanoma. (2024) pubmed
- Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma. (2025) pubmed